Ensuring In-House Audit Programmes are Strategically Focused through Implementing Risk Models
Hosted By : Pharma IQSeptember 10, 2010
Rate this Podcast:
(3.9 Stars | 8 Votes)
About this Podcast...
20% of all clinical trials are now subject to regulatory audits! With inspectors’ expectations continually evolving and an increasing number of regulatory warnings, relating to record keeping and informed consent, it is more important than ever to comply with GCP and be inspection ready. Dr. Peter Schiemann, Global Head Quality Risk Management at F. Hoffmann - La Roche, joins Andrea Charles from Pharma IQ, to discuss the key drivers behind why more organisations are adopting a quality risk based model, when auditing multiple clinical sites and ensuring in-house audit programmes are strategically focused.
What are the 7 Deadly Sins of Quality Assurance and Quality Control? |
Rate this Podcast:
(3.9 Stars | 8 Votes)
Events of Interest
-
Taking EDC to the next level: Moving from point solutions to an eClinical ecosystem
April 4, 2013
Register Now -
Site Quality Management and Risk-Based Monitoring: A New Approach
December 4, 2012
Register Now -
Electronic Laboratory Notebooks Online
December 2, 2011
Register Now -
Improving Sample Management QC and Reducing Costs by Regular Sample Auditing
October 5, 2011
Register Now





Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!